Search

• ViiV Healthcare presents three-year switch data for Dovato (dolutegravir/lamivudine) confirming long-term, non-inferior efficacy with no virologic failure versus continuation of TAF-based regimens of at least three drugs

  Media

  The Phase 3 TANGO study is the 3rd trial to provide long-term evidence for Dovato reinforcing its use as a viable switch for people with HIV

  https://www.gsk.com/en-gb/media/press-releases/viiv-presents-three-year-switch-data-for-dovato/

  First published: 29 September 2021

• ARIA study shows superior efficacy of Triumeq® for treatment-naïve women living with HIV

  Media

  ViiV Healthcare today presented 48-week data from the phase IIIb, open-label, international, multi-centre ARIA study

  https://www.gsk.com/en-gb/media/press-releases/aria-study-shows-superior-efficacy-of-triumeq-for-treatment-naïve-women-living-with-hiv/

  First published: 18 July 2016

• ViiV Healthcare submits regulatory applications for the first HIV maintenance regimen comprising only two medicines

  Media

  ViiV Healthcare submits regulatory applications for the first HIV maintenance regimen comprising only two medicines

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-submits-regulatory-applications-for-the-first-hiv-maintenance-regimen-comprising-only-two-medicines/

  First published: 01 June 2017

• ViiV Healthcare receives EU marketing authorisation for Juluca (dolutegravir/rilpivirine), the first 2-drug regimen, once-daily, single-pill for the treatment of HIV

  Media

  Juluca maintains viral suppression with two drugs in the smallest single pill regimen

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-eu-marketing-authorisation-for-juluca-dolutegravirrilpivirine-the-first-2-drug-regimen-once-daily-single-pill-for-the-treatment-of-hiv/

  First published: 21 May 2018

• ViiV Healthcare receives CHMP Positive Opinion for Tivicay EU label update with GEMINI study data for the 2-drug regimen of Tivicay + lamivudine

  Media

  Committee for Medicinal Products for Human Use has adopted a Positive Opinion on a Type II variation regulatory application for Tivicay

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-chmp-positive-opinion-for-tivicay-eu-label-update-with-gemini-study-data-for-the-2-drug-regimen-of-tivicay-plus-lamivudine/

  First published: 16 November 2018

• Juluca (dolutegravir/rilpivirine), the first single pill, 2-drug regimen, for the maintenance treatment of HIV, granted marketing approval by Japan Ministry of Health, Labour and Welfare

  Media

  The Ministry of Health, Labour and Welfare has approved Juluca Combination Tablets for the maintenance treatment of (HIV-1) infection.

  https://www.gsk.com/en-gb/media/press-releases/juluca-dolutegravirrilpivirine-the-first-single-pill-2-drug-regimen-for-the-maintenance-treatment-of-hiv-granted-marketing-approval-by-japan-ministry-of-health-labour-and-welfare/

  First published: 26 November 2018

• ViiV Healthcare presents data from second Dovato (dolutegravir/lamivudine) switch study confirming non-inferior efficacy and no virologic failure versus a broad range of regimens of at least 3 drugs

  Media

  ViiV Healthcare today presented 48-week data from the SALSA study at the International AIDS Society Conference 2021

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-data-from-second-dovato-switch-study/

  First published: 17 July 2021

• ViiV Healthcare announces US FDA approval of Cabenuva (cabotegravir, rilpivirine) for use every two months, expanding the label of the first and only complete long-acting HIV treatment

  Media

  Cabenuva is now approved for administration as few as six times a year for virologically suppressed adults living with HIV.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-us-fda-approval-of-cabenuva-cabotegravir-rilpivirine-for-use-every-two-months-expanding-the-label-of-the-first-and-only-complete-long-acting-hiv-treatment/

  First published: 01 February 2022

• ViiV Healthcare and the Medicines Patent Pool sign new voluntary licensing agreement to expand access to innovative long-acting HIV prevention medicine

  Media

  Selected generic manufacturers will have the opportunity to develop, manufacture and supply generic versions of cabotegravir LA for PrEP

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-and-the-medicines-patent-pool-sign-new-voluntary-licensing-agreement/

  First published: 28 July 2022

• GSK presents scientific advances to improve patient outcomes at the American Association for the Study of Liver Diseases’ The Liver Meeting® 2023

  Media

  New data from the B-Together phase IIb trial contribute to the development of a functional cure for people living with CHB.

  https://www.gsk.com/en-gb/media/press-releases/gsk-presents-scientific-advances-to-improve-patient-outcomes-at-the-american-association-for-the-study-of-liver-diseases-the-liver-meeting-2023/

  First published: 11 October 2023